Zach Sweeney is a Venture Partner at Versant and has broad experience growing and leading successful multifunctional drug discovery groups, including small molecule, biotherapeutic and genetic medicine discovery platforms.

Zach was formerly the CEO and co-founder of Interline Therapeutics, and prior to that was the Chief Scientific Officer at Denali Therapeutics, where he led the growth of the discovery portfolio and research group. Zach was also a leader in the drug discovery groups at Revolution Medicines, Novartis, Genentech and Roche.

• 

  Venture Partner in Versant Ventures

  HARNESSING THE POWER OF SCIENCE, GLOBALLY